World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
139
Citations
77854
World Ranking
1747
National Ranking
998

Farhad Ravandi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Farhad Ravandi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,796 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Farhad Ravandi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Farhad Ravandi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 139 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Farhad Ravandi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on hematology within the broader field of medicine, contributing extensively to acute myeloid leukemia and related hematological malignancies.

Their recent research publications have appeared in several well-regarded journals. Notable papers include:

  • "Acute myeloid leukemia: current progress and future directions," Blood Cancer Journal, 2021
  • "2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party," Blood, 2021
  • "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission," New England Journal of Medicine, 2020
  • "Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges," Cancer Discovery, 2020
  • "Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics," Nature Communications, 2020

These publications highlight a focus on acute myeloid leukemia, including molecular mechanisms, minimal residual disease assessment, and novel therapeutic approaches.

Frequent collaborators in their research include:

  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Nicholas J. Short
  • Elias Jabbour
  • Courtney D. DiNardo

Their work has been published extensively in several core scientific venues, such as:

  • Blood
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Cancer
  • Blood Advances

Farhad Ravandi's research fields cover several interconnected specialties, including hematology, genetics, molecular biology, public health, and oncology. Their work touches on topics with a strong clinical and translational focus, such as:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Multiple Myeloma Research and Treatments

This body of work represents a commitment to expanding understanding of blood cancers and developing improved treatment modalities. Through collaboration with prominent coauthors and contributions across multiple high-impact journals, Farhad Ravandi has become an active figure within the research community focusing on hematologic malignancies.

Best Publications

  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

    Hagop Kantarjian;Jean-Pierre J. Issa;Craig S. Rosenfeld M.D.;John M. Bennett

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

    Hagop Kantarjian;Susan O'Brien;Farhad Ravandi;Jorge Cortes

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Miguel A. Sanz;Miguel A. Sanz;Pierre Fenaux;Martin S. Tallman;Elihu H. Estey

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

    Farhad Ravandi;Eli Estey;Dan Jones;Stefan Faderl

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

    Hagop M. Kantarjian;Farhad Ravandi;Susan OBrien;Jorge Cortes

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing Medicine in the USA is highly competitive, there are multiple alternative online degrees and career routes in healthcare that offer rewarding opportunities. Nursing is one of the most popular fields, and finding affordable education options is crucial for many students.

For those interested in advanced practice, there are cheap np programs that allow registered nurses to become nurse practitioners with flexible, cost-effective study options. If you’re already a registered nurse seeking to advance your educational credentials, you may want to explore what is the cheapest rn to bsn program online to maximize value and convenience.

Students can also consider the cheapest rn to bsn online programs to bridge the gap between an associate and bachelor's degree. For those pursuing leadership or academic roles within nursing, online doctoral studies are becoming more accessible, and information on affordable phd in nursing pathways can help open the door to research and higher education positions.

These online degrees offer flexibility and cost savings, making healthcare careers accessible for a wider range of students.

Best Scientists Citing Farhad Ravandi

Trending Scientists

Recently Published Articles